Trial reportPflugers Archiv : European journal of physiology2025
Intravascular volume expansion is prominently overestimated via hemoglobin concentration: a placebo-controlled and cross-over trial.
Trial report in Pflugers Archiv : European journal of physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Albumin 20% in surgical and critically ill patients; a comprehensive review.Critical care (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Blood volume (BV) expansion by means of intravenous infusion of colloids is an established procedure in clinical interventions. The essential questions of how much of the infused fluid stays in the circulation according to measured changes in hemoconcentration are uncertain. A placebo-controlled, single-blinded, and cross-over design was implemented to assess the effect of a definite increment in BV on hemodilution, as determined by hemoglobin concentration ([Hb]). Healthy women (n = 17) and men (n = 19) matched by sex, age (age = 26 ± 4 vs. 27 ± 3 yr, P = 0.522), and physical activity were subjected in a blind manner to the intravenous infusion of placebo-sham (PBO-sham) via saline infusion (10 mL; BD 0.9% NaCl) or albumin (volume equivalent to 10% of BV; Albumin CSL 20%). [Hb] was slightly reduced (-2.4%) after the PBO-sham infusion. For the albumin infusion, the amount of fluid infused ranged from 325 to 810 mL (547 ± 112 mL) in order to elicit a 10% increment in BV in each individual. [Hb] was markedly reduced (-17.2%) (13.8 ± 1.6 vs. 11.5 ± 1.4 g·dL
Indexed as
Identifiers
41042303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.